This page shows the latest Qsiva news and features for those working in and with pharma, biotech and healthcare.
This followed a knockback for Vivus' drug in October 2012, when regulators refused Qsiva (Vivus' preferred brand name for Europe) due to cardiovascular safety concerns.
In October 2012, Vivus faced a knockback from the European Medicines Agency (EMA) for obesity treatment Qsiva (phentermine/topiramate ER), despite receiving prior approval in the US. ... Like its rival Qsiva, Belviq is also recommended in the US.
There is still a long way to go before liraglutide reaches the market, however, and Novo should expect a tough regulatory challenge if the fate of recent obesity treatments Qsymia/ Qsiva
Still no recommendation for Qsiva in Europe. Vivus faced a major setback yesterday when a European Medicines Agency (EMA) committee upheld its earlier decision to reject the company's obesity drug ... has retained its position and said a cardiovascular
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...